Mural Oncology PLCNASDAQ:MURA
- LAST PRICE3.5000
- TODAY'S CHANGE (%)0.0400 (1.1561%)
- Bid / Lots3.3800/ 10
- Ask / Lots3.5500/ 5
- Open / Previous Close3.4800 / 3.4600
- Day Range
- 52 Week Range
- Volume87,760
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MURA |
|---|---|---|
| 09:32 ET | 369 | 3.48 |
| 09:38 ET | 100 | 3.5 |
| 09:41 ET | 300 | 3.54 |
| 10:08 ET | 8334 | 3.48 |
| 10:10 ET | 300 | 3.5299 |
| 10:12 ET | 3180 | 3.4901 |
| 10:14 ET | 200 | 3.52 |
| 10:15 ET | 3902 | 3.495 |
| 10:24 ET | 3180 | 3.47 |
| 10:26 ET | 2365 | 3.4697 |
| 10:39 ET | 100 | 3.48 |
| 10:42 ET | 100 | 3.4501 |
| 10:53 ET | 288 | 3.4588 |
| 11:13 ET | 100 | 3.45 |
| 11:15 ET | 1200 | 3.45 |
| 11:18 ET | 400 | 3.45 |
| 11:20 ET | 212 | 3.45 |
| 11:22 ET | 12100 | 3.45 |
| 11:24 ET | 400 | 3.45 |
| 11:26 ET | 100 | 3.45 |
| 11:27 ET | 100 | 3.45 |
| 11:29 ET | 100 | 3.45 |
| 11:31 ET | 100 | 3.45 |
| 11:33 ET | 400 | 3.45 |
| 11:36 ET | 100 | 3.45 |
| 11:38 ET | 100 | 3.45 |
| 11:42 ET | 100 | 3.45 |
| 11:44 ET | 100 | 3.45 |
| 11:45 ET | 300 | 3.46 |
| 11:56 ET | 700 | 3.46 |
| 12:03 ET | 600 | 3.45 |
| 12:09 ET | 100 | 3.45 |
| 12:14 ET | 5700 | 3.456 |
| 12:16 ET | 400 | 3.44 |
| 12:18 ET | 200 | 3.4699 |
| 12:20 ET | 900 | 3.4885 |
| 12:21 ET | 400 | 3.4999 |
| 12:32 ET | 1100 | 3.48 |
| 12:34 ET | 4278 | 3.4795 |
| 12:36 ET | 2700 | 3.46 |
| 12:41 ET | 800 | 3.45 |
| 12:50 ET | 800 | 3.45 |
| 12:57 ET | 800 | 3.45 |
| 01:06 ET | 100 | 3.45 |
| 01:17 ET | 1320 | 3.45 |
| 01:21 ET | 800 | 3.45 |
| 01:28 ET | 800 | 3.45 |
| 01:35 ET | 800 | 3.45 |
| 01:37 ET | 100 | 3.45 |
| 01:39 ET | 488 | 3.4412 |
| 01:42 ET | 100 | 3.45 |
| 01:44 ET | 100 | 3.45 |
| 01:51 ET | 800 | 3.45 |
| 01:53 ET | 100 | 3.45 |
| 02:00 ET | 800 | 3.45 |
| 02:06 ET | 800 | 3.45 |
| 02:13 ET | 800 | 3.45 |
| 02:15 ET | 602 | 3.45 |
| 02:18 ET | 200 | 3.45 |
| 02:20 ET | 200 | 3.45 |
| 02:22 ET | 200 | 3.45 |
| 02:24 ET | 200 | 3.45 |
| 02:26 ET | 300 | 3.45 |
| 02:27 ET | 200 | 3.45 |
| 02:29 ET | 600 | 3.47 |
| 02:38 ET | 1130 | 3.5 |
| 02:42 ET | 800 | 3.47 |
| 03:00 ET | 100 | 3.47 |
| 03:16 ET | 1280 | 3.483 |
| 03:20 ET | 300 | 3.485 |
| 03:21 ET | 100 | 3.49 |
| 03:41 ET | 100 | 3.5 |
| 03:43 ET | 200 | 3.495 |
| 03:48 ET | 1600 | 3.49 |
| 03:52 ET | 100 | 3.495 |
| 03:54 ET | 200 | 3.495 |
| 03:57 ET | 239 | 3.5 |
Jul 2, 2024
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:15PM ET on Tuesday Jul 02, 2024 by Dow Jones
4:15PM ET on Tuesday Jul 02, 2024 by Dow Jones
Jun 28, 2024
DJ Mural Oncology Initiated at Buy by Rodman & Renshaw, from 12:57PM ET on Friday Jun 28, 2024 by Dow Jones
12:57PM ET on Friday Jun 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mural Oncology PLC | 58.6M | -0.3x | --- |
OKYO Pharma Ltd | 45.6M | -0.1x | --- |
Anebulo Pharmaceuticals Inc | 57.1M | -6.1x | --- |
Oncolytics Biotech Inc | 78.1M | -3.6x | --- |
Immix Biopharma Inc | 56.8M | -2.4x | --- |
Aerovate Therapeutics Inc | 55.3M | -0.7x | --- |
Company Information
Mural Oncology plc is a clinical-stage oncology company. The Company is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. It leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.
Contact Information
- Headquarters
- 10 Earlsfort TerraceDUBLIN, Ireland D02 T380
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Scott Jackson
- Director
- Caroline Loew
- Chief Financial Officer
- Adam Cutler
- Chief Medical Officer
- Vicki Goodman
- Chief Legal Officer
- Maiken Keson-Brookes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $58.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 16.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-11.49 |
Book Value | $15.81 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
